Recent studies have shown that BRAF V600-mutated CRC and BRAF non-V600-mutated CRC have different prognoses and different sensitivities to drugs; furthermore, the proposed BRAF mutations can be grouped into three classes (1, 2, and 3) [8,9] Currently, combinatorial therapy with cytotoxic chemotherapeutic agents and molecular targeted drugs (bevacizumab) are recommended as the first-line therapy for KRAS/BRAF-mutant CRC [10]. The gene discussed is BRAF; the disease is colorectal carcinoma.